PATENT CLAIM ANALYSIS

Application Number: 15861679
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-09
Patent Classification: ["514", "179000"]

Abstract:
The present invention relates to the formulation of steroids, including neurosteroids (e.g., allopregnanolone (ALP)) in edible oils to enhance their absorption when administered, e.g., orally or transmucosally to a patient.

Claim (Index 17):
A method of treating, reducing, and/or mitigating symptoms associated with and/or caused by traumatic brain injury, Alzheimer's disease, epilepsy, anxiety, fragile X syndrome, post-traumatic stress disorder, lysosomal storage disorders (Niemann-Pick type C disease), depression (including post-partum depression), premenstrual dysphoric disorder, alcohol craving, and smoking cessation in a subject in need thereof, comprising administration to the subject orally or transmucosally a composition of  claim 1 .

Metadata:
- Claim Count in Document: 20.0
- Percentile: 86.0
- Lexical Diversity: 1.25806
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14345385', '15649460', '15649583', '15508233', '15143586']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7195041419069399
- 35 USC 102 Novelty (BERT): 0.6061878183503825
- Combined Prediction Score: 0.7081725095512842
- Mean Citation Score: 327.488172
- Max Citation Score: 554.6102
- Similarity Product: 396.5210226439833

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test